TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00519285
Drug: Prednisone or Prednisolone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marketed formulation~5 mg twice daily PO from day 1 continuously
Study: NCT00081939
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
Study: NCT00003760
Drug: irofulven
Normalized name: Irofulven
DrugBank: Irofulven (DB05786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
Study: NCT00001626
Drug: antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antithymocyte globulin
Study: NCT00001626
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclosporine
Study: NCT04414631
Drug: Conestat alfa
Normalized name: conestat alfa
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.
Study: NCT02576327
Drug: Tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron Hydrochloride Injection 5mg (Day 1-6)
Study: NCT02576327
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
Study: NCT02576327
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
Study: NCT04567810
Drug: anti-SARS-CoV-2 IgY
Normalized name: Anti-SARS-CoV-2 IgY
DrugBank: Anti-SARS-CoV-2 IgY (DB16356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
Study: NCT03434028
Drug: Early Vasopressors
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met.
Study: NCT02595606
Drug: 0.3% Sodium Hyaluronate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: five times per day for the intervention of eye drop
Study: NCT00179699
Drug: CC-5013
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00179699
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03179943
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
Study: NCT03179943
Drug: Guadecitabine
Normalized name: Guadecitabine
DrugBank: Guadecitabine (DB11918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
Study: NCT01261143
Drug: BK-C-0701
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet, 8 weeks
Study: NCT03047772
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine dose of Atorvastatin therapy
Study: NCT03047772
Drug: Intensive Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive dose of Atorvastatin therapy
Study: NCT03047772
Drug: Low dose BMMSC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Study: NCT03047772
Drug: Middle dose BMMSC
Normalized name: wheat middlings extract
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Study: NCT03047772
Drug: High dose BMMSC
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Study: NCT03047772
Drug: Transplantation
Normalized name: Transplantation antigen
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
Study: NCT00049998
Drug: topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04297072
Drug: Rivaroxaban (Xarelto, BAY-597939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.
Study: NCT02744339
Drug: Riociguat
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adempas up-titrated to max. 1.5mg TID
Study: NCT00383409
Drug: multivitamins
Normalized name: MULTIVITAMINS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02667886
Drug: X4P-001
Normalized name: CXCR4 INHIBITOR X4P-001
DrugBank: Mavorixafor (DB05501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous, oral dosing
Study: NCT02667886
Drug: axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous, oral dosing
Study: NCT00985270
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03391856
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant
Study: NCT00509405
Drug: potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 times 10 mEq per day, oral for 24 months
Study: NCT03455777
Drug: AKCEA-ANGPTL3-LRX
Normalized name: Akcea ttr lrx
DrugBank: Eplontersen (DB16199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single open-label cohort
Study: NCT02484547
Drug: Aducanumab (BIIB037)
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose
Study: NCT02781311
Drug: Setipiprant
Normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setipiprant tablets, orally, BID for 24 weeks.
Study: NCT02781311
Drug: Finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride tablet, orally, once daily for 24 weeks.
Study: NCT01813305
Drug: CSTC1
Normalized name: Cortisone
DrugBank: Cortisone acetate (DB01380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
Study: NCT02786836
Drug: 13C-Methacetin
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate.
Study: NCT00550212
Drug: neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HKI-272, Single-dose capsule and solution
Study: NCT02394665
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~* Concurrent during Radiation Therapy: 75 mg/m\^2 orally for 6 weeks;~* Post-radiation, adjuvant therapy: 150 mg/m\^2 - 200 mg/m\^2 orally daily on days 1 - 5 of each cycle.
Study: NCT00627354
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00627354
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00627354
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00627354
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01621204
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).
Study: NCT01621204
Drug: IVIG infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed
Study: NCT03383003
Drug: Nexium
Normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy
Study: NCT02780895
Drug: Human Stem Cells
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.~For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.~To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.~After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery.
Study: NCT04639986
Drug: Sacituzumab Govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
Study: NCT04639986
Drug: Eribulin Mesylate Injection
Normalized name: Eribulin Mesylate Injection
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
Study: NCT04639986
Drug: Gemcitabine Injection
Normalized name: gemcitabine Injection
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
Study: NCT04639986
Drug: Vinorelbine injection
Normalized name: vinorelbine Injection
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
Study: NCT01486381
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (s.c., under the skin)
Study: NCT04786756
Drug: Bupivacaine 0.25% Injectable Solution
Normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg Bupivacaine (0.25%)
Study: NCT03641456
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib on days 1 and 15 at the dose level of 1.3mg/m2. Patients discontinued treatment if they had progressive disease or or unacceptable toxic effects not controlled with dose modifications.
Study: NCT03641456
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The investigators gave patients oral lenalidomide 25mg on days 1 to 21 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of lenalidomide on days 1 to 21 at the dose level of 10mg. Patients discontinued treatment if they had progressive disease or unacceptable toxic effects not controlled with dose modifications.
Study: NCT03641456
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.
Study: NCT03383003
Drug: Amolin
Normalized name: Ethamolin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy
Study: NCT01098526
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
Study: NCT03383003
Drug: Flagyl
Normalized name: Flagyl
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (Flagyl) 500 mg tid daily for 7 days in the non-bismuth quadruple therapy
Study: NCT00814645
Drug: Sodium Nitrite Inhalation Solution
Normalized name: Sodium Nitrite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
Study: NCT00338260
Drug: Comparator : atenolol /Duration of Treatment : 5 Years
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03512119
Drug: Lumacaftor-Ivacaftor treatment
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lumacaftor-Ivacaftor treatment during one year
Study: NCT00257868
Drug: Rivastigmine prevention of delirium
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00005675
Drug: Oral bovine type I collagen
Normalized name: Bovine type I collagen
DrugBank: Bovine type I collagen (DB10771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mcg of CI daily for 15 months
Study: NCT01155791
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV 75 mg/m2
Study: NCT01155791
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg, orally
Study: NCT02729935
Drug: Parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 40 mg of intravenous parecoxib 30 min before surgery
Study: NCT00288522
Drug: Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00049400
Drug: BMS-247550
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
Study: NCT02039661
Drug: Lidocaine Spray
Normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: These patients received 2 puff lidocaine spray
Study: NCT00914290
Drug: Baclofen IR
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated baclofen tablet 5 mg per capsule
Study: NCT00280865
Drug: Tesaglitazar
Normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00280865
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03023423
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive atezolizumab 1200 mg intravenously.
Study: NCT03023423
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive daratumumab 16 mg/kg intravenously.
Study: NCT00801411
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01498783
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil, bolus dose of 500 mg/m\^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
Study: NCT00484276
Drug: NGR-hTNF
Normalized name: NGR-hTNF
DrugBank: Tengonermin (DB16689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
Study: NCT02146222
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01444898
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
Study: NCT00066508
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04292314
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
Study: NCT04022005
Drug: Chidamide, Rituximab, Gemcitabine,Oxaliplatin
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy.
Study: NCT01227928
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib 800 mg daily for 24 months
Study: NCT01084993
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
Study: NCT04292314
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyurea medication (5 to 15mg/kg) per day for 8 consecutive months up to 10 months.
Study: NCT04292314
Drug: Honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural honey(2.5 mg/kg dissolved in 250 ml water) per day for 8 consecutive months up to 10 months.
Study: NCT04292314
Drug: Deferoxamine
Normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: deferoxamine (SubQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/day)for 8 consecutive months up to 10 months.
Study: NCT05988034
Drug: Avacopan
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT05988034
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05988034
Drug: Placebo for avacopan
Normalized name: Avacopan
DrugBank: AVAC (DB05441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT05988034
Drug: Placebo for moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01267981
Drug: Standard Diet + 500 ml of polyethyleneglycol
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
Study: NCT01267981
Drug: Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.